Organizations Filed Purposes:
THE PRIMARY RESPONSIBILITY OF DIALYSIS CLINIC INC. (DCI) IS TO PERCEIVE, INITIATE, AND PROVIDE COMPREHENSIVE PATIENT CARE. WE SERVE SOCIETY BY PROVIDING CARE FOR PATIENTS WITH CHRONIC KIDNEY DISEASE.
TO INITIATE AND PROVIDE COMPREHENSIVE CARE FOR PATIENTS WITH END-STAGE RENAL DISEASE.
THE DIALYSIS DIVISION IS THE PRINCIPAL ACTIVITY OF OUR COMPANY AND IS PRIMARILY INVOLVED WITH PROVIDING KIDNEY DIALYSIS AND RELATED SERVICES FOR INSURED AND UNINSURED PATIENTS. RENAL DIALYSIS IS NOT AN ELECTIVE MEDICAL PROCEDURE, BUT A LIFE-SUSTAINING TREATMENT FOR PEOPLE LIVING WITH KIDNEY FAILURE. PROVIDING THESE MEDICALLY-NECESSARY TREATMENTS FURTHERS OUR EXEMPT PURPOSE OF PROVIDING QUALITY OUTPATIENT CARE FOR ALL PATIENTS WITH END-STAGE RENAL DISEASE, WHICH INCLUDES THE APPLICATION OF COMPANY RESOURCES FOR SCIENTIFIC AND EDUCATIONAL PURPOSES FOR THE PREVENTION, EARLY DETECTION, AND TREATMENT OF RENAL DISEASE. DURING FYE 2019, 2,193,987 DIALYSIS PROCEDURES WERE PERFORMED. A SIGNIFICANT PORTION OF OUR DIALYSIS CHARGES ARE COVERED BY MEDICARE AND STATE MEDICAID PROGRAMS, WHILE THE REMAINING COSTS ARE PAID BY THIRD PARTY INSURERS, AND CHARITY CARE. CHARITY CARE IS PROVIDED TO PATIENTS WHO MEET CERTAIN CRITERIA UNDER OUR CHARITY CARE POLICY WITHOUT CHARGE OR AT AMOUNTS LESS THAN OUR ESTABLISHED RATES.
THE LAB DIVISION PROVIDES SPECIALIZED LABORATORY TESTING AND DIAGNOSTIC PROCEDURES FOR DIALYSIS FACILITIES AND PATIENTS WITH KIDNEY DISEASE AND RENAL FAILURE. A VARIETY OF LABORATORY TESTS TO ANALYZE DIFFUSED TOXINS FROM THE BLOOD ARE NECESSARY TO MONITOR THE CLINICAL COURSE OF PATIENTS AND THE OVERALL EFFECTIVENESS OF RENAL DIALYSIS. THESE TESTS ARE NECESSARY IN THE TREATMENT OF RENAL DISEASE, AND FURTHERS OUR EXEMPT PURPOSE OF PROVIDING QUALITY CARE FOR PATIENTS WITH CHRONIC RENAL DISEASE BY CONTINUALLY IMPROVING OUR PROCESSES IN MEASURING LEVELS OF KIDNEY FUNCTION TO PRODUCE OPTIMAL PATIENT OUTCOMES. FOR FYE 09/30/2019, 897,934 PATIENT TESTS WERE PERFORMED.
THE SUPPLY AND PHARMACY DIVISION PROVIDES MEDICAL SUPPLIES, INCLUDING BUT NOT LIMITED TO NUTRITIONAL SUPPLEMENTS, DRUGS, AND HOME DIALYSIS SUPPLIES FOR DCI FACILITIES AND PROVIDES PRESCRIPTION MEDICATIONS FOR DCI EMPLOYEES.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| William E Wood | PRESIDENT | 40 | $1,092,285 |
| Amit Nahata | PHYSICIAN | 40 | $595,088 |
| Jessie Ganjoo | PHYSICIAN | 40 | $581,148 |
| James E Attrill | VICE PRESIDENT | 40 | $512,523 |
| Rose Smith | SENIOR OPERATIONS DIRECTOR | 40 | $496,210 |
| Mostafa Amr | PHYSICIAN | 40 | $489,026 |
| Margaret Williams | DIRECTOR OF COMPLIANCE | 40 | $470,140 |
| Doug Johnson | VICE CHAIRMAN | 40 | $448,890 |
| Stuart Redpath | CHIEF OPERATIONS OFFICER | 40 | $434,199 |
| Mary Hobeika | CHIEF STRATEGY OFFICER | 40 | $197,241 |
| Joe Swearingen | ASSISTANT TREASURER | 40 | $193,626 |
| Donovan Schultz | CHIEF FINANCIAL OFFICER | 40 | $167,343 |
| James Perry | DIRECTOR | 20 | $37,103 |
| Ken Johnson | DIRECTOR | 2 | $0 |
| H Keith Johnson | CHAIRMAN | 32 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202022309349302282_public.xml